

Evaluation of drug efficacy and discovery of pharmacodynamics biomarkers of a new anti-CD40 antibody lead compound (PB101) for the treatment of Pemphigus, a rare intractable skin disease

PB immune therapeutics



IMMUNOLOGY	Lead
Product Type	Immunoglobulin product (mAb)
Indication	Pemphigus vulgaris
Target	Human CD40
MoA(Mechanism of Action)	
Competitiveness	<ul style="list-style-type: none"> - Higher functionality (higher antagonism, lower agonism) - Unique binding site - Linear form binding
Development Stage	Lead
Route of Administration	Intravenous